Cutler Group’s aTyr Pharma ATYR Stock Holding History

Cutler Group’s Portfolio ATYR Stock Details ATYR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-85	Closed	–	–	5814
2022 Q1	$0	Sell	85 -2,758	-97%	-$15.6K	﹤0.01%	6205
2021 Q4	$21K	Sell	2,843 -12,681	-82%	-$106K	﹤0.01%	3100
2021 Q3	$140K	Buy	+15,524	New	+$92.9K	0.01%	1635

Other funds holding ATYR

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Tikvah Management Charlotte, North Carolina $323M AUM 69.61% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Cutler Group's ATYR Position: Q2 2022 in Review

Cutler Group sold out of aTyr Pharma (ATYR) in Q2 2022, closing a stake of 85 shares.

Cutler Group first reported a position in ATYR in Q3 2021 and held it in 3 quarters. The position peaked at $140K in Q3 2021. 36 funds tracked by Wall St. Rank hold ATYR as of Q2 2022.

Cutler Group reported no remaining aTyr Pharma position as of Q2 2022 after selling out during the quarter.
Cutler Group sold 85 aTyr Pharma shares in Q2 2022.
Cutler Group first reported a position in aTyr Pharma in Q3 2021 and held it in 3 quarters.
Cutler Group's aTyr Pharma position peaked at $140K in Q3 2021.
36 funds tracked by Wall St. Rank held aTyr Pharma as of Q2 2022.

Based on Cutler Group's 13F filing for Q2 2022, filed 4 Aug 2022.